Podrobno

Biomarkers for predicting malignant transformation of premalignant lesions of the larynx : a systematic review
ID Rodrigo, Juan Pablo (Avtor), ID Zidar, Nina (Avtor), ID Gale, Nina (Avtor), et al.

.pdfPDF - Predstavitvena datoteka, prenos (1,41 MB)
MD5: C2F10EC30C262874668C8CBC9B646922
URLURL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2075-4418/16/2/236 Povezava se odpre v novem oknu

Izvleček
Background/Objectives: Premalignant laryngeal lesions carry a variable risk of malignant transformation to squamous cell carcinoma. Identifying reliable biomarkers that predict malignant transformation could improve patient management and surveillance strategies. The objective of this work is to perform a systematic review of the literature on biomarkers that predict malignant transformation of premalignant laryngeal lesions. Methods: We conducted a systematic review following PRISMA 2020 guidelines. The PubMed, Scopus and Embase databases, and Google Scholar were searched for studies published between January 2011 and November 2025. Studies investigating biomarkers that predict malignant transformation of histopathologically confirmed premalignant laryngeal lesions were included. Risk of bias was assessed using the ROBINS-I tool. Results: From 166 initially identified records, 11 studies met the inclusion criteria, including 730 patients. These studies investigated diverse biomarker categories such as protein markers (cortactin, FAK, NANOG, SOX2, CSPG4), immune markers (tumor-infiltrating lymphocytes, immune gene signatures), microRNAs (miR-183-5p, miR-155-5p, miR-106b-3p), and genetic markers (chromosomal instability, PIK3CA amplification and mutations, FGFR3 mutations). Five studies provided adequate follow-up data on transformation outcomes. Most studies showed a moderate to serious risk of bias primarily due to limited confounder control and incomplete reporting. Conclusions: While several promising biomarker candidates have been identified, the evidence base remains limited due to small sample sizes, heterogeneous methodologies, and inadequate follow-up data. Cortactin/FAK protein expression and immune signatures are the most promising but require validation in larger, well-designed prospective cohorts.

Jezik:Angleški jezik
Ključne besede:ROBINS-I, biomarkers, laryngeal dysplasia, malignant transformation, premalignant lesions, systematic review
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:MF - Medicinska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2026
Št. strani:14 str.
Številčenje:Vol. 16, iss. 2, art. 236
PID:20.500.12556/RUL-183304 Povezava se odpre v novem oknu
UDK:616-006
ISSN pri članku:2075-4418
DOI:10.3390/diagnostics16020236 Povezava se odpre v novem oknu
COBISS.SI-ID:267970563 Povezava se odpre v novem oknu
Datum objave v RUL:11.06.2026
Število ogledov:288
Število prenosov:211
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Diagnostics
Skrajšan naslov:Diagnostics
Založnik:MDPI
ISSN:2075-4418
COBISS.SI-ID:519963673 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:ROBINS-I, biološki označevalci, displazija grla, maligna transformacija, premaligne lezije, sistematični pregled

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj